50% off Premium Yearly

Managing Partner at New Edge Capital
Member since: Dec '21 · 197 Opinions
Underwriters, scarcity and index inclusion will hold up this stock for the first month, then the fundamentals will apply after the lock-up comes off. He owned this privately and now publicly. When their costs go down and the share prices goes up, SPACX is the winner. Margins are good and will improve. There are many parts to this business, and the most important is enterprise AI. Don't chase it here, though. Would buy if the price returns to the IPO, which may not happen. No stock has more momentum than this.
Consistent earnings, fair valuation, and a great drug pipeline.